We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

89bio Inc (ETNB) USD0.001

Sell:$4.50 Buy:$4.54 Change: $0.44 (10.78%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.44 (10.78%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.44 (10.78%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

89Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company's lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death. The Company is evaluating the potential opportunity for pegozafermin in these fibrosis stage F4 patients. SHTG is a condition identified by severely elevated levels of triglycerides. The Company has initiated its Phase II trial (ENTRIGUE) in SHTG patients.

Contact details

142 Sansome Street, Second Floor
San Francisco
United States
+1 (415) 4329270

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$163.91 million
Shares in issue:
39.03 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Rohan Palekar
    Chief Executive Officer, Director
  • Ryan Martins
    Chief Financial Officer
  • Ram Waisbourd
    Chief Operating Officer, Chief Business Officer
  • Quoc Le-Nguyen
    Chief Technical Operations Officer and Head of Quality
  • Hank Mansbach
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.